Efficacy and safety of FYX-051 compared with allopurinol in Patients with Hyperuricemia (with or without Gout)

Trial Profile

Efficacy and safety of FYX-051 compared with allopurinol in Patients with Hyperuricemia (with or without Gout)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Topiroxostat (Primary) ; Allopurinol
  • Indications Hyperuricaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanwa Kagaku Kenkyusho
  • Most Recent Events

    • 26 Apr 2017 Planned number of patients changed to 200.
    • 31 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top